Treatment Group (T) and description | EpiCC scores | Percent coverage | % Improvement of homologous vs heterologous coverage a | ||||
---|---|---|---|---|---|---|---|
 | Vaccine | Challenge | PCV2a ORF2 b | PCV2b ORF2 c | PCV2a ORF2 b | PCV2b ORF2 c | |
T02 homologous treatment | cPCV2a | PCV2a | 10.42 d | 7.51 | 100.00 | 72.05 | 36.46 |
T04 heterologous treatment | cPCV2a | PCV2b | 7.51 | 10.25 d | 73.28 | 100.00 |